Division of Molecular & Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK.
Department of Radiology, The Christie NHS Foundation Trust, Manchester, UK.
BMC Cancer. 2020 Nov 30;20(1):1165. doi: 10.1186/s12885-020-07613-7.
The primary aim was to test the hypothesis that deriving pre-treatment 3D magnetic resonance tumour volume (mrTV) quantification improves performance characteristics for the prediction of loco-regional failure compared with standard maximal tumour diameter (1D) assessment in patients with squamous cell carcinoma of the anus undergoing chemoradiotherapy.
We performed an early evaluation case-control study at two UK centres (2007-2014) in 39 patients with loco-regional failure (cases), and 41 patients disease-free at 3 years (controls). mrTV was determined using the summation of areas method (Vol). Reproducibility was assessed using intraclass concordance correlation (ICC) and Bland-Altman limits of agreements. We derived receiver operating curves using logistic regression models and expressed accuracy as area under the curve (ROC).
The median time per patient for Vol quantification was 7.00 (inter-quartile range, IQR: 0.57-12.48) minutes. Intra and inter-observer reproducibilities were generally good (ICCs from 0.79 to 0.89) but with wide limits of agreement (intra-observer: - 28 to 31%; inter-observer: - 28 to 46%). Median mrTVs were greater for cases (32.6 IQR: 21.5-53.1 cm) than controls (9.9 IQR: 5.7-18.1 cm, p < 0.0001). The ROC for mrT-size predicting loco-regional failure was 0.74 (95% CI: 0.63-0.85) improving to 0.82 (95% CI: 0.72-0.92) when replaced with mrTV (test for ROC differences, p = 0.024).
Preliminary results suggest that the replacement of mrTV for mrT-size improves prediction of loco-regional failure after chemoradiotherapy for squamous cell carcinoma of the anus. However, mrTV calculation is time consuming and variation in its reproducibility are drawbacks with the current technology.
本研究旨在验证假设,即在接受放化疗的肛门鳞癌患者中,与标准最大肿瘤直径(1D)评估相比,通过预先处理的 3D 磁共振肿瘤体积(mrTV)定量评估来预测局部区域失败,是否能提高预测的性能特征。
我们在英国的两个中心(2007-2014 年)进行了一项早期的病例对照研究,纳入了 39 例局部区域失败(病例)和 41 例 3 年无病(对照组)的患者。使用面积总和法(Vol)确定 mrTV。使用组内一致性相关系数(ICC)和 Bland-Altman 协议范围评估重复性。我们使用逻辑回归模型绘制受试者工作特征曲线,并表示准确性为曲线下面积(ROC)。
每位患者进行 Vol 定量的中位时间为 7.00 分钟(四分位距,IQR:0.57-12.48)。内和观察者间的重复性通常较好(ICC 范围为 0.79-0.89),但协议范围较宽(内观察者:-28%至 31%;观察者间:-28%至 46%)。病例的中位 mrTV 大于对照组(32.6 IQR:21.5-53.1cm)(9.9 IQR:5.7-18.1cm,p<0.0001)。mrT 大小预测局部区域失败的 ROC 为 0.74(95%CI:0.63-0.85),当用 mrTV 替代时,ROC 提高至 0.82(95%CI:0.72-0.92)(ROC 差异检验,p=0.024)。
初步结果表明,在接受放化疗的肛门鳞癌患者中,用 mrTV 替代 mrT 大小可提高局部区域失败的预测准确性。然而,mrTV 的计算耗时,并且目前技术的重复性存在差异是其缺点。